Alnylam Licenses RNAi Patents to Qiagen
Alnylam Pharmaceuticals said this week that it has granted Qiagen non-exclusive access to use technology covered under the Kreutzer-Limmer patent family to provide RNAi research products and services.
The intellectual property covers small interfering RNAs and their use to mediate RNAi in mammalian cells.
Qiagen already offers siRNA libraries and high-throughput siRNA synthesis technology.
Galapagos to Acquire BioFocus for $36.5 Million in Stock